Dexcom announced the Dexcom G7 15 Day Continuous Glucose Monitoring System for people over the age of 18 with diabetes will ...

DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the Dexcom G7 15 Day Continuous Glucose ...

Dexcom (NSDQ:DXCM) announced today that it plans to launch its G7 15 Day continuous glucose monitor (CGM) in the U.S. next ...

Dexcom’s “Smart Basal” has received FDA clearance for people with type 2 diabetes using long-acting insulin. The feature will ...

Dexcom's Apple Watch app will be ready to go when the device launches in April, the company told the Wall Street Journal. The app, which will not need to seek pre-market approval from the FDA thanks ...

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, will showcase its expanding focus on Dexcom CGM ...

If you are a new investor, healthcare stocks can provide numerous diversification benefits to your portfolio and help enhance ...

LONDON--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced both the launch of Dexcom ONE+, a CGM ...

A software defect could cause the app to terminate, resulting in missed alerts or alarms. Dexcom required users to update the app.

DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the FDA has cleared Dexcom Smart Basal, the first and only CGM-integrated basal insulin dosing optimizer designed ...

A medical technology firm specialising in continuous glucose monitoring systems for diabetes is set to relocate to Maxis Business Park in Bracknell.